Tag Archives: Acid sphingomyelinase deficiency

August, 2016

  • 2 August

    Amgen and Advaxis Enter Cancer Immunotherapies Collaboration

    THOUSAND OAKS, Calif. and PRINCETON, N.J., Aug. 2, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient’s immune system to respond against the unique …

June, 2015

  • 8 June

    Breakthrough Status Granted to Genzyme’s Rare Enzyme Replacement Drug

    Genzyme, a Sanofi company, recently announced that its investigational enzyme-replacement therapy was granted Breakthrough Therapy designation from US health regulators. The company said that the agency granted the status to its olipudase alfa for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick …